Medtronic PLC $MDT Shares Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS lifted its position in shares of Medtronic PLC (NYSE:MDT) by 3.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 484,787 shares of the medical technology company’s stock after acquiring an additional 16,100 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Medtronic were worth $46,913,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Corundum Trust Company INC acquired a new position in shares of Medtronic during the third quarter worth about $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic during the fourth quarter worth about $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the third quarter worth about $29,000. Board of the Pension Protection Fund acquired a new position in shares of Medtronic during the fourth quarter worth about $29,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Medtronic during the fourth quarter worth about $29,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic led a $100M financing round and signed a commercial agreement with Pulnovo Medical, strengthening its respiratory/commercial footprint and signaling targeted investment in growth adjacencies. Medtronic leads $100M investment in Pulnovo Medical
• Positive Sentiment: Medtronic completed the acquisition of CathWorks for $585M, adding the FFRangio® coronary diagnostic platform — a strategic bolt‑on to its cardiovascular franchise that should be accretive over time. Medtronic completes acquisition of CathWorks
• Positive Sentiment: Medtronic and GE HealthCare announced a digital integration between Stealth AXiS navigation and bkActiv intraoperative ultrasound, strengthening the neurosurgery product ecosystem and potential cross‑sell opportunities. Medtronic And GE HealthCare Tie Neurosurgical Imaging Upgrade To MDT Valuation
• Neutral Sentiment: Industry reports (wearable injectors market) list Medtronic among key players — a long‑term tailwind for home/chronic care products but not an immediate earnings driver. Wearable Injectors Market Report 2026
• Neutral Sentiment: Several articles revisit Wall Street analyst recommendations on MDT — analysts are broadly optimistic, which supports medium‑term sentiment but has limited impact when investors focus on near‑term catalysts. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: News about competitor Intuitive Surgical reporting strong results shows the medtech sector remains active; strong beats elsewhere don’t always lift the whole group, highlighting selective investor flows. Intuitive Surgical Earnings Show Big Beats Don’t Always Spark Stock Rallies
• Negative Sentiment: Market coverage notes Medtronic’s share price moved notably lower today (a larger dip than the broader market), reflecting either profit‑taking, rotation away from large medtech names, or short‑term reaction to headlines despite the strategic positives above. Medtronic (MDT) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Analyst Upgrades and Downgrades

MDT has been the topic of a number of research analyst reports. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Leerink Partners reaffirmed an “outperform” rating and issued a $119.00 target price on shares of Medtronic in a report on Tuesday, March 10th. Citigroup dropped their target price on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. CICC Research began coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “outperform” rating for the company. Finally, Argus dropped their target price on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a report on Monday, April 6th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $109.25.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is owned by corporate insiders.

Medtronic Trading Down 3.2%

Shares of Medtronic stock opened at $82.25 on Wednesday. Medtronic PLC has a 12-month low of $79.93 and a 12-month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The stock has a market cap of $105.60 billion, a PE ratio of 22.91, a price-to-earnings-growth ratio of 2.21 and a beta of 0.75. The company has a 50-day moving average of $90.80 and a two-hundred day moving average of $95.53.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period last year, the company posted $1.38 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were given a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.5%. Medtronic’s dividend payout ratio is currently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).